… factor receptor inhibitors, gefitinib and erlotinib, are used as standard salvage therapy for
advanced non-small-cell lung cancer (NSCLC). The aim of the present study was to compare …

… who had progressed after gefitinib treatment, were included in this study; patients received …
study. Most patients who benefit from erlotinib had also benefited from prior gefitinib treatment…

… Forty-five patients included in this study were enrolled in prospective trials of gefitinib or
erlotinib … in a phase II randomized study of erlotinib with or without carboplatin and paclitaxel in …

… gefitinib and erlotinib treatment. In this study, we retrospectively evaluated the difference
in efficacy between these two agents in Taiwanese patients with advanced NSCLC treated at …

… after progression on EGFR TKI therapy and subsequent response to erlotinib. Seven of the
… progression on EGFR TKI therapy: 3 after gefitinib therapy and the other 4 after gefitinib and …

… Hence, response to prior gefitinib therapy may be a predictive maker for subsequent erlotinib
therapy [9, 11, 14]. In our study, subsequent erlotinib therapy was effective in 38% of cases …

… Thus, we undertook this phase 2b/3 study of afatinib in patients with lung adenocarcinoma
… of previous erlotinib or gefitinib treatment, a group for whom few, if any, approved treatment …

… treatment, we hypothesized that, in patients with acquired resistance to erlotinib or gefitinib,
continued treatment with erlotinib or … study resumed treatment with the same drug (erlotinib or …

… study was to identify predictive factors for erlotinib treatment … In the present study, we found
that the PFS of prior gefitinib is … for the clinical efficacy of erlotinib following gefitinib failure. A …

… [5], the randomized, placebo-controlled study performed by the NCIC comparing erlotinib …
patient subset that was treated with erlotinib, compared with those treated with placebo (median…